Georgian Halcu, Filip Cristian Mureșan, Andrei Niculae, Anca Evsei-Seceleanu, Mihai-Emilian Lapadat, Mihai Adrian Cerbu, Mihail Ceausu
{"title":"PD-L1 Expression and Tumor Microenvironment Dynamics in Diffuse Large B-Cell Lymphoma: Immunophenotypic Insights.","authors":"Georgian Halcu, Filip Cristian Mureșan, Andrei Niculae, Anca Evsei-Seceleanu, Mihai-Emilian Lapadat, Mihai Adrian Cerbu, Mihail Ceausu","doi":"10.25122/jml-2025-0078","DOIUrl":null,"url":null,"abstract":"<p><p>Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of B-cell non-Hodgkin lymphoma (NHL) and is characterized by significant biological and clinical heterogeneity. The programmed death 1 (PD-1)/ programmed death-ligand 1 (PD-L1) immune checkpoint pathway plays a crucial role in tumor immune evasion; however, its diagnostic and prognostic relevance in DLBCL remains unclear. We retrospectively analyzed 66 cases of DLBCL diagnosed between 2017 and 2024 at a single institution. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissues using antibodies against PD-L1, PD-1, CD4, CD8, and CD68. Clinical data and histopathological features were correlated with marker expression. Statistical analyses were conducted using IBM SPSS 25, with a significance level set at <i>P</i> < 0.05. PD-L1 expression (greater than 1%) in tumor cells was infrequent (6/66 cases), while immune cell PD-L1 positivity was prevalent (39/66 cases). PD-1 positivity was observed in five tumor samples and 40.9% of stromal immune cells. A significant association was found between tumoral PD-L1 expression and histological subtype (<i>P</i> = 0.015), with anaplastic variants showing higher expression levels. Positive PD-1 expression in immune cells was significantly associated with female gender (<i>P</i> = 0.044). High CD68 expression correlated with a lower Ann Arbor stage (<i>P</i> = 0.040) and tumor morphology (<i>P</i> = 0.010). CD4 and CD8 expression levels showed no significant correlations with clinicopathological features. PD-L1 and PD-1 expression patterns in DLBCL highlight their potential relevance for immune evasion and prognosis, particularly in anaplastic variants. The tumor microenvironment, especially macrophage infiltration, plays a complex role in disease progression. Further studies are needed to validate these findings and investigate therapeutic implications.</p>","PeriodicalId":16386,"journal":{"name":"Journal of Medicine and Life","volume":"18 5","pages":"463-471"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12207696/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicine and Life","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25122/jml-2025-0078","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of B-cell non-Hodgkin lymphoma (NHL) and is characterized by significant biological and clinical heterogeneity. The programmed death 1 (PD-1)/ programmed death-ligand 1 (PD-L1) immune checkpoint pathway plays a crucial role in tumor immune evasion; however, its diagnostic and prognostic relevance in DLBCL remains unclear. We retrospectively analyzed 66 cases of DLBCL diagnosed between 2017 and 2024 at a single institution. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissues using antibodies against PD-L1, PD-1, CD4, CD8, and CD68. Clinical data and histopathological features were correlated with marker expression. Statistical analyses were conducted using IBM SPSS 25, with a significance level set at P < 0.05. PD-L1 expression (greater than 1%) in tumor cells was infrequent (6/66 cases), while immune cell PD-L1 positivity was prevalent (39/66 cases). PD-1 positivity was observed in five tumor samples and 40.9% of stromal immune cells. A significant association was found between tumoral PD-L1 expression and histological subtype (P = 0.015), with anaplastic variants showing higher expression levels. Positive PD-1 expression in immune cells was significantly associated with female gender (P = 0.044). High CD68 expression correlated with a lower Ann Arbor stage (P = 0.040) and tumor morphology (P = 0.010). CD4 and CD8 expression levels showed no significant correlations with clinicopathological features. PD-L1 and PD-1 expression patterns in DLBCL highlight their potential relevance for immune evasion and prognosis, particularly in anaplastic variants. The tumor microenvironment, especially macrophage infiltration, plays a complex role in disease progression. Further studies are needed to validate these findings and investigate therapeutic implications.
期刊介绍:
The Journal of Medicine and Life publishes peer-reviewed articles from various fields of medicine and life sciences, including original research, systematic reviews, special reports, case presentations, major medical breakthroughs and letters to the editor. The Journal focuses on current matters that lie at the intersection of biomedical science and clinical practice and strives to present this information to inform health care delivery and improve patient outcomes. Papers addressing topics such as neuroprotection, neurorehabilitation, neuroplasticity, and neuroregeneration are particularly encouraged, as part of the Journal''s continuous interest in neuroscience research. The Editorial Board of the Journal of Medicine and Life is open to consider manuscripts from all levels of research and areas of biological sciences, including fundamental, experimental or clinical research and matters of public health. As part of our pledge to promote an educational and community-building environment, our issues feature sections designated to informing our readers regarding exciting international congresses, teaching courses and relevant institutional-level events.